Danske Bank’s Larimar Therapeutics LRMR Stock Holding History

Danske Bank’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-19,670	Closed	-$149K	–	1213
2024 Q1	$149K	Buy	+19,670	New	+$153K	﹤0.01%	956

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Danske Bank's LRMR Position: Q2 2024 in Review

Danske Bank sold out of Larimar Therapeutics (LRMR) in Q2 2024, closing a stake of 19,670 shares — an estimated $149K sold.

Danske Bank first reported a position in LRMR in Q1 2024 and held it in 1 quarter. The position peaked at $149K in Q1 2024. 107 funds tracked by Wall St. Rank hold LRMR as of Q2 2024.

Danske Bank reported no remaining Larimar Therapeutics position as of Q2 2024 after selling out during the quarter.
Danske Bank sold 19,670 Larimar Therapeutics shares in Q2 2024, an estimated $149K.
Danske Bank first reported a position in Larimar Therapeutics in Q1 2024 and held it in 1 quarter.
Danske Bank's Larimar Therapeutics position peaked at $149K in Q1 2024.
107 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2024.

Based on Danske Bank's 13F filing for Q2 2024, filed 18 Mar 2026.